|
|
Article: InterMune Falls On Lowered Guidance; Reports Positive Data.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Associate Managing Editor
InterMune Inc. said late Wednesday that it saw positive top-line results in its confirmatory Phase III trial of oritavancin in complicated skin/skin-structure infections caused by Gram-positive bacteria. It also gave guidance for its second-quarter sales and dropped its full-year estimates.
It was the latter bit of news that investors considered more, dropping InterMune's stock (NASDAQ:ITMN) $8.36 Thursday, or 33.3 percent, to close at $16.74.
Actimmune (interferon gamma-1b) is approved in the U.S. for chronic granulomatous disease and severe, malignant osteopetrosis. The company said it is expecting between $30 ...